ProQR Therapeutics « Terug naar discussie overzicht

ProQR Therapeutics 2019

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 58 59 60 61 62 63 64 65 66 67 68 ... 129 130 131 132 133 » | Laatste

Omlaag ↓

[verwijderd] 10 juli 2019 04:50

you where the one that said Aescap sold at least 1/2 of its holding of proqr.
i asked you for a link or anything and y have not provided.

as for agtc and aescap .. here it is whalewisdom.com/schedule13d/view/stic...

i am asking people to back up what they say...

Tom3 10 juli 2019 09:04

quote:
joel12 schreef op 10 juli 2019 04:50:
you where the one that said Aescap sold at least 1/2 of its holding of proqr.
i asked you for a link or anything and y have not provided.

as for agtc and aescap .. here it is whalewisdom.com/schedule13d/view/stic...

i am asking people to back up what they say...

Interesting news. On January 18, 2019 it was reported that Aescap 2.0 is the owner of approximately 1.4 million ProQR shares (=3.7%). This used to be 1.8 million so they have sold 400k. You can find this on this IEX board:

ir.proqr.com/sec-filings/sec-filing/s...

[verwijderd] 10 juli 2019 09:55

so its not more than half as you wrote few days ago right?
they sold some 30% which makes sense

Tom3 10 juli 2019 11:00

Yes in my memory it was more than 30%, sorry. What is the difference between the Nightstar and AGTC technolog? Seems that the Biogen deal hasn`t lifted the price of AGTC.

[verwijderd] 10 juli 2019 13:23

the difference is the AAV vector .. the buyout didnt move AGTC because this one has always been late in delivering results and failed one , but has explanation for why.. it has results for the second one soon and if good conjoined with presenting a bigger undisclosed pipeline.. the company could close the valuation gap between it and nightstar and the rest.

4finance 10 juli 2019 16:34

Zo, Affimed deels er uit en ProQR er in. Dat Affimed zit totaal geen beweging meer in..... Ja steeds verder naar beneden ;-) Nu maar hopen dat we met ProQR niet weer afdalen richting $3,50 Zeg nooit nee tegen Bio's ;-)

Tom3 10 juli 2019 17:59

quote:
joel12 schreef op 10 juli 2019 13:23:
the difference is the AAV vector .. the buyout didnt move AGTC because this one has always been late in delivering results and failed one , but has explanation for why.. it has results for the second one soon and if good conjoined with presenting a bigger undisclosed pipeline.. the company could close the valuation gap between it and nightstar and the rest.

Isn`t the gene to be transferred into the eye not too big for the AAV vector? From ProQR/University of Nijmegen information I have understood that the Usher gene is way too big for this.

You are a shareholder of AGTC too?

Tom3 10 juli 2019 18:26

quote:
4finance schreef op 10 juli 2019 16:34:
Zo, Affimed deels er uit en ProQR er in. Dat Affimed zit totaal geen beweging meer in..... Ja steeds verder naar beneden ;-) Nu maar hopen dat we met ProQR niet weer afdalen richting $3,50 Zeg nooit nee tegen Bio's ;-)

Nou ja ik had een andere keuze gemaakt, maar fijn dat je weer in ProQR zit. Het aandeel hangt er inderdaad bij als een natte krant. Op hoop van zegen.

[verwijderd] 10 juli 2019 18:36

ok guys .. nothing new on this board... want something interesting? proqr has something interesting... a new VP of business development. from Takeda.
hold tight for something big in the works... but for that you have to believe in the company and its management which has done wonders so far.. and the future is in my view many times more brighter.

[verwijderd] 10 juli 2019 18:58

the AAV will work when need to augument .. i.e to add gene material. the biggest problem with AAV is that for each disease you need to change the delivery mechanism,,, AGTC however differentiates by that its using the same delivery across opht. diseases. in addition there are other complications, w AAV and thats why PROQR may be the best out of all the companies because its delivery mechanism is the most beautiful.

i did invest also in AGTC because the valuation compared to the potential is very good. it does have a good chance.. but PRQR I believe not only for the optham. frenchise but its overall potential esp the RNA editing is a better overall company.. however sometimes there are companies which have a mismatched valuation compared to potential and development. agtc is one of them.

4finance 10 juli 2019 19:14

quote:
Tom3 schreef op 10 juli 2019 18:26:
[...]

Nou ja ik had een andere keuze gemaakt, maar fijn dat je weer in ProQR zit. Het aandeel hangt er inderdaad bij als een natte krant. Op hoop van zegen.

Affimed heb ik nog heel veel van...

Tom3 10 juli 2019 19:59

quote:
4finance schreef op 10 juli 2019 19:14:
[...]

Affimed heb ik nog heel veel van...

Oh, dan is het goed. Achteraf is het meestal niet zo moeilijk.... Ga me toch eens verdiepen in dat AGTC. Dat Aescap 2.0 heeft zich tot nu toe nog niet vaak vergist.

Tom3 10 juli 2019 22:16

quote:
joel12 schreef op 9 juli 2019 18:57:
you are right .. usher this weekend no news. y have to wait until 2020 to get any news.

In the meantime AGTC may come up with good news from its trial and it can become a competitor .

if there is no conviction better to move to other stocks. imho

AGTC a competitor in Usher 2A? Please read the following article (it is in Dutch but may be can use Google translate)

www.ushersyndroom.nl/genetische-thera...

[verwijderd] 11 juli 2019 07:22

did you buy Proqr for Usher>?

Tom3 11 juli 2019 08:34

quote:
joel12 schreef op 11 juli 2019 07:22:
did you buy Proqr for Usher>?

You are a non-believer with regard to their vision 2023 strategy?

www.globenewswire.com/news-release/20...

[verwijderd] 11 juli 2019 12:39

i wondered just Tom if you bought the company for its Usher drug. because if thats the case its not a good reason . there are other companies at lower valuation that have a chance in ophthalmology AGTC, ISEE and others.

Tom3 11 juli 2019 14:06

quote:
joel12 schreef op 11 juli 2019 12:39:
i wondered just Tom if you bought the company for its Usher drug. because if thats the case its not a good reason . there are other companies at lower valuation that have a chance in ophthalmology AGTC, ISEE and others.

Usher (is it dead according to you???) should be a great value driver, I stil think this is still the case in the long run as it is the cornerstone of their business plan. In January they talked about hiring salespeople already. Without Usher they need a strong partner asap. How about the Axiomer and CF partnering you deemed likely?

[verwijderd] 11 juli 2019 14:20

i am not saying Usher is dead. Usher results will only come in next year.
the question is again for your maybe for others why to invest in Proqr where at current valuation is many times over AGTC for example .. lets say.

i know my answer but wanted to know how others see it

TD_01 11 juli 2019 15:56

Ik denk dat er een gat in de bodem zit. We keep on going.

Tom3 11 juli 2019 15:58

quote:
joel12 schreef op 11 juli 2019 14:20:
i am not saying Usher is dead. Usher results will only come in next year.
the question is again for your maybe for others why to invest in Proqr where at current valuation is many times over AGTC for example .. lets say.

i know my answer but wanted to know how others see it

Ok, well I think RNA therapy is commercially more viable than DNA modification. De Boer has made this clear in his last presentation. Why invest in AGTC when this is already on the market and sold to a powerhouse like Biogen?

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 58 59 60 61 62 63 64 65 66 67 68 ... 129 130 131 132 133 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	15 mei 2024 22:00
Koers	1,910
Verschil	-0,075 (-3,78%)
Hoog	1,990
Laag	1,880
Volume	120.844
Volume gemiddeld	171.821
Volume gisteren	249.624

ProQR Therapeutics 2019

Meedoen aan de discussie?

Direct naar Forum

Detail

ProQR Therapeutics NV nieuws meer